Specification
| Target | PD-1 |
| Clone | Tislelizumab |
| Isotype | Human IgG4(S228P/E233P/F234V/L235A/D265A/R409K)-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | |
| Recommended Dilution Buffer | PBS, pH 7.85 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors). |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |